Developer docs
API playgroundTry for free, no card

Search company profiles

Domain Associates

Full company profile

uuid0000nub

Namestring
Domain Associates
Legal namestring
DomainVC
Websiteurl
domainvc.com
Company typeenum
Private
Founded yearint
1985
Descriptiontext

Domain Associates (operating as DomainVC) is a San Diego-based venture capital firm founded in 1985 with an exclusive focus on the life sciences sector. The firm was the investment advisor to the first VC fund dedicated to biotechnology and has subsequently managed nine dedicated biotech VC funds, accumulating $2.8 billion in assets under management. Its portfolio spans biopharmaceutical, medical device, and diagnostic companies, with 194 companies funded over the firm's history resulting in 90 IPOs and 110 M&A exits and a combined market capitalization of $190 billion across portfolio companies.

The firm generates revenue through standard venture capital economics, including management fees charged on assets under management and carried interest on successful investment exits. Its limited partners are institutional investors committing capital to its dedicated biotech funds, and the firm sources new investments through partner networks, industry conferences, and direct relationships with life sciences entrepreneurs. The team consists of six active partners (James Blair, Brian Halak, Kim Kamdar, Nicole Vitullo, plus an additional partner listed in the team roster), one partner emeritus (Jesse Treu), a managing director of finance and administration (Lisa Kraeutler), and two venture partners (Dennis Podlesak, Eckard Weber). The firm has experienced the loss of two senior leaders, Partner Brian Dovey (In Memoriam 2023) and Partner and CFO Kathleen Schoemaker (In Memoriam 2016).

Domain Associates does not produce technology products; its underlying capability is investing acumen, sector specialization, and relationship networks developed over nearly four decades. The firm was recognized in 2025 by Greenlight as one of the Top 50 Venture Capital Firms for Medical Device Startups. As a private firm, revenue is not publicly disclosed and no subsidiaries, parent company, or public listing is identified.

Short descriptiontext

Domain Associates is a San Diego-based venture capital firm founded in 1985 that invests exclusively in life sciences, managing $2.8 billion across nine biotech VC funds with 194 portfolio companies and 90 IPOs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
venture capital funds, biotech investments, life sciences financing, medical device investing, pharmaceutical venture capital
NAICS code1 code
  • Portfolio Management and Investment Advice523940
Product category
Venture Capital — Life Sciences
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Management
TypeManaged Services
Description

Domain Associates generates revenue through management fees charged on assets under management and carried interest (performance fees) on successful investment exits including IPOs and M&A transactions. As the investment manager of 9 biotech VC funds, the firm earns fees from limited partners (institutional investors) who commit capital to its funds.

domainvc.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Domain Associates (DomainVC) is a venture capital firm that manages biotech-focused investment funds and provides equity capital to early and growth-stage biopharmaceutical, medical device, and diagnostic companies. Founded in 1985 as investment advisor to the first VC fund dedicated to biotech, the firm has since managed 9 subsequent biotech VC funds totaling $2.8 billion in assets under management.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 194 biopharm, device and diagnostic companies funded to successful exits
+3 more records
Product overview1 text field

DomainVC operates as a venture capital firm focused exclusively on the biotechnology sector. The company serves as investment advisors to the first VC fund dedicated to biotech and has managed 9 subsequent biotech VC funds. The single unified offering is their VC fund management and investment advisory services for biotech companies in the biopharm, medical device, and diagnostic sectors. The portfolio companies they have funded (194 companies) represent their investment portfolio managed through these VC fund structures.

Product and service1 record
1Biotech Venture Capital Funds
CategoryVenture Capital Fund Management
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

RA Capital is a Boston-based specialist life sciences investor that builds dedicated biotech and medtech funds, directly comparable to Domain's model of running multiple biotech-focused VC funds targeting therapeutics, devices, and diagnostics.

TypeDirect peer
Description

ARCH is one of the largest dedicated biotech-focused VC firms, managing multiple life sciences funds and co-founding companies across therapeutics, diagnostics, and devices — directly comparable to Domain in fund structure, vertical specialization, and stage focus.

TypeDirect peer
Description

Atlas Venture is an early-stage life sciences-focused VC firm that builds and funds biotech startups across modalities, directly comparable to Domain's therapeutics and platforms investing approach with a similarly concentrated sector focus.

TypeDirect peer
Description

OrbiMed is a healthcare-dedicated investment firm across private equity, venture, and royalty strategies covering biopharma, medical devices, and diagnostics — directly comparable to Domain in its exclusive life sciences mandate and multi-fund structure.

TypeDirect peer
Description

Versant is a healthcare-focused VC firm operating multiple funds and an in-house biotech incubator (Inception), closely comparable to Domain's long-standing practice of seeding and funding biotech, device, and diagnostic companies through dedicated life sciences funds.

TypeDirect peer
Description

Flagship Pioneering is a biotech-focused firm that creates and funds platform companies across therapeutics and diagnostics — directly comparable to Domain in its exclusive life sciences mandate and its approach of building and backing biotech ventures through multiple funds.

TypeDirect peer
Description

5AM Ventures is an early-stage life sciences venture firm investing across biopharma and platform technologies, directly comparable to Domain in its focused biotech mandate and similar fund-vintage approach.

TypeDirect peer
Description

Venrock is a venture firm with a longstanding healthcare and biotech practice investing in therapeutics, diagnostics, and devices — directly comparable to Domain in life sciences specialization and early/growth-stage investing across similar modalities.

TypeBroad incumbent
Description

NEA is a large, multi-stage venture firm with a dedicated healthcare practice investing in biopharma, devices, and digital health — comparable to Domain as a fellow life sciences investor, but operating as a broad incumbent across many sectors rather than a biotech-exclusive specialist.

TypeBroad incumbent
Description

Kleiner Perkins is a multi-stage venture firm with a dedicated life sciences practice investing across therapeutics, devices, and digital health — comparable to Domain in life sciences investing, though operating as a broad tech-and-health incumbent rather than an exclusively biotech-focused specialist.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment316 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Domain Associates

Venture Capital — Life Sciencesdomainvc.com

Domain Associates is a San Diego-based venture capital firm founded in 1985 that invests exclusively in life sciences, managing $2.8 billion across nine biotech VC funds with 194 portfolio companies and 90 IPOs.

What Domain Associates does

Domain Associates (operating as DomainVC) is a San Diego-based venture capital firm founded in 1985 with an exclusive focus on the life sciences sector. The firm was the investment advisor to the first VC fund dedicated to biotechnology and has subsequently managed nine dedicated biotech VC funds, accumulating $2.8 billion in assets under management. Its portfolio spans biopharmaceutical, medical device, and diagnostic companies, with 194 companies funded over the firm's history resulting in 90 IPOs and 110 M&A exits and a combined market capitalization of $190 billion across portfolio companies.

The firm generates revenue through standard venture capital economics, including management fees charged on assets under management and carried interest on successful investment exits. Its limited partners are institutional investors committing capital to its dedicated biotech funds, and the firm sources new investments through partner networks, industry conferences, and direct relationships with life sciences entrepreneurs. The team consists of six active partners (James Blair, Brian Halak, Kim Kamdar, Nicole Vitullo, plus an additional partner listed in the team roster), one partner emeritus (Jesse Treu), a managing director of finance and administration (Lisa Kraeutler), and two venture partners (Dennis Podlesak, Eckard Weber). The firm has experienced the loss of two senior leaders, Partner Brian Dovey (In Memoriam 2023) and Partner and CFO Kathleen Schoemaker (In Memoriam 2016).

Domain Associates does not produce technology products; its underlying capability is investing acumen, sector specialization, and relationship networks developed over nearly four decades. The firm was recognized in 2025 by Greenlight as one of the Top 50 Venture Capital Firms for Medical Device Startups. As a private firm, revenue is not publicly disclosed and no subsidiaries, parent company, or public listing is identified.

Domain Associates firmographics

Firmographics
Name
Domain Associates
Legal name
DomainVC
Website
https://domainvc.com
Company type
Private
Founded year
1985
Operating status
Operating
Headcount range
11–50 employees
Short description
Domain Associates is a San Diego-based venture capital firm founded in 1985 that invests exclusively in life sciences, managing $2.8 billion across nine biotech VC funds with 194 portfolio companies and 90 IPOs.
Ownership category
akta.pro rank

Where Domain Associates is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Domain Associates business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Investment Management: Domain Associates generates revenue through management fees charged on assets under management and carried interest (performance fees) on successful investment exits including IPOs and M&A transactions. As the investment manager of 9 biotech VC funds, the firm earns fees from limited partners (institutional investors) who commit capital to its funds.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Domain Associates product offering

Product offering

Core offering

Domain Associates (DomainVC) is a venture capital firm that manages biotech-focused investment funds and provides equity capital to early and growth-stage biopharmaceutical, medical device, and diagnostic companies. Founded in 1985 as investment advisor to the first VC fund dedicated to biotech, the firm has since managed 9 subsequent biotech VC funds totaling $2.8 billion in assets under management.

Product overview

DomainVC operates as a venture capital firm focused exclusively on the biotechnology sector. The company serves as investment advisors to the first VC fund dedicated to biotech and has managed 9 subsequent biotech VC funds. The single unified offering is their VC fund management and investment advisory services for biotech companies in the biopharm, medical device, and diagnostic sectors. The portfolio companies they have funded (194 companies) represent their investment portfolio managed through these VC fund structures.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biotech Venture Capital Funds

Quantifiable outcome

  • 194 biopharm, device and diagnostic companies funded to successful exits
  • +3 more outcomes

Companies that use Domain Associates

Customer profile

Segments3 records

Ideal customer profiles4 records

Domain Associates technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Domain Associates partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves5 records

Expansion highlights3 records

Domain Associates competitors and assessment

Company assessment

Direct peers

  • RA Capital Management: RA Capital is a Boston-based specialist life sciences investor that builds dedicated biotech and medtech funds, directly comparable to Domain's model of running multiple biotech-focused VC funds targeting therapeutics, devices, and diagnostics.
  • ARCH Venture Partners: ARCH is one of the largest dedicated biotech-focused VC firms, managing multiple life sciences funds and co-founding companies across therapeutics, diagnostics, and devices — directly comparable to Domain in fund structure, vertical specialization, and stage focus.
  • Atlas Venture: Atlas Venture is an early-stage life sciences-focused VC firm that builds and funds biotech startups across modalities, directly comparable to Domain's therapeutics and platforms investing approach with a similarly concentrated sector focus.
  • OrbiMed: OrbiMed is a healthcare-dedicated investment firm across private equity, venture, and royalty strategies covering biopharma, medical devices, and diagnostics — directly comparable to Domain in its exclusive life sciences mandate and multi-fund structure.
  • Versant Ventures: Versant is a healthcare-focused VC firm operating multiple funds and an in-house biotech incubator (Inception), closely comparable to Domain's long-standing practice of seeding and funding biotech, device, and diagnostic companies through dedicated life sciences funds.
  • Flagship Pioneering: Flagship Pioneering is a biotech-focused firm that creates and funds platform companies across therapeutics and diagnostics — directly comparable to Domain in its exclusive life sciences mandate and its approach of building and backing biotech ventures through multiple funds.
  • 5AM Ventures: 5AM Ventures is an early-stage life sciences venture firm investing across biopharma and platform technologies, directly comparable to Domain in its focused biotech mandate and similar fund-vintage approach.
  • Venrock: Venrock is a venture firm with a longstanding healthcare and biotech practice investing in therapeutics, diagnostics, and devices — directly comparable to Domain in life sciences specialization and early/growth-stage investing across similar modalities.

Broad incumbents

  • New Enterprise Associates (NEA): NEA is a large, multi-stage venture firm with a dedicated healthcare practice investing in biopharma, devices, and digital health — comparable to Domain as a fellow life sciences investor, but operating as a broad incumbent across many sectors rather than a biotech-exclusive specialist.
  • Kleiner Perkins: Kleiner Perkins is a multi-stage venture firm with a dedicated life sciences practice investing across therapeutics, devices, and digital health — comparable to Domain in life sciences investing, though operating as a broad tech-and-health incumbent rather than an exclusively biotech-focused specialist.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Domain Associates social profiles

Digital presence

Domain Associates financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Domain Associates leadership team

Management profile

Number of profiles

Profiles8 records

Domain Associates funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Domain Associates M&A and investment

M&A and investment

M&A

Investments316 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Domain Associates

What does Domain Associates do?

Domain Associates (DomainVC) is a venture capital firm that manages biotech-focused investment funds and provides equity capital to early and growth-stage biopharmaceutical, medical device, and diagnostic companies. Founded in 1985 as investment advisor to the first VC fund dedicated to biotech, the firm has since managed 9 subsequent biotech VC funds totaling $2.8 billion in assets under management.

Is Domain Associates a public or private company?

Domain Associates is a private company. It is classified as management employee owned and is currently operating.

When was Domain Associates founded?

Domain Associates was founded in 1985. It employs 11 to 50 people.

Where is Domain Associates based?

Domain Associates is headquartered in San Diego, United States, in the North America region.

How does Domain Associates make money?

One revenue line is on record: investment Management.

Who are Domain Associates's main competitors?

Direct peers on record are RA Capital Management, ARCH Venture Partners, Atlas Venture, OrbiMed, Versant Ventures, Flagship Pioneering, 5AM Ventures and Venrock. Broad incumbents are New Enterprise Associates (NEA) and Kleiner Perkins.

Does Domain Associates have an API?

No public API is recorded for Domain Associates.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ForbesThis Veterinary Epidemiologist Raised $6.2 Million To Launch An Essential Fatty Acid SupplementDr. Stephanie Venn-Watson, a veterinary epidemiologist, discovered C15:0, an essential fatty acid, after studying dolphins and launched the vegan supplement fatty15. She raised $6.2 million in Series A funding led by Domain Associates. The supplement aims to lower proinflammatory biomarkers and reduce risks of diabetes and cardiovascular disease.PR NewswireDomain Associates and Catalys Pacific Launch Exalys Therapeutics to Develop Portfolio of Next-Generation EP4 AntagonistsDomain Associates and Catalys Pacific launched Exalys Therapeutics Inc. on July 16, 2020, with a $15 million Series A financing and a licensed platform of next-generation EP4 receptor antagonists from Eisai Co. Ltd. in Japan. The new company will develop first-in-class therapies targeting inflammatory disorders, with an initial focus on preventing postoperative delirium—a condition affecting 30% or more of patients over 65 undergoing surgery and representing an estimated $150 billion in annual U.S. healthcare costs. Exalys plans to advance its lead candidate through proof-of-concept trials using biomarker-supported clinical studies to address this unmet medical need.Food Business NewsStudies link a saturated fat to reduced risk of diseasesSeraphina Therapeutics announced plans to commercialize pentadecanoic acid (C15:0), a saturated fat linked in recent studies to reduced risks of inflammation, cardiovascular disease, and non-alcoholic fatty liver disease. The company has secured $5.5 million in Series A funding from Domain Associates to support the launch of C15:0 dietary supplements in the fall and food fortification ingredients early next year.PR NewswireAspen Neuroscience Announces Board of Directors and Scientific Advisory BoardAspen Neuroscience, a private biotechnology company based in San Diego, announced the formation of its Board of Directors and Scientific Advisory Board to guide the development of its autologous neuron replacement therapy for Parkinson disease. The company previously raised $6.5 million in seed funding for its program that uses neurons derived from induced pluripotent stem cells created from each patient's own cells. The newly established boards include distinguished industry veterans and academic leaders expected to guide Aspen through clinical trials and toward regulatory approval.FinSMEsAspen Neuroscience Raises $6.5M in Seed FundingAspen Neuroscience, a San Diego-based biotech, raised $6.5M in seed funding led by Domain Associates and Axon Ventures. The company develops autologous cell therapies for Parkinson's disease, with its lead product ANPD001 in IND-enabling studies. It also has a gene-edited therapy ANPD002 in research for familial forms.socaltech.comAtara Biotherapeutics Leases New Space In Thousand OaksAtara Biotherapeutics leased a 90,000-square-foot building in the Conejo Spectrum in Thousand Oaks, according to developer SARES-REGIS Group. The 15-year lease is the first of nine industrial buildings the developer is building at the business park. The company is venture-backed by multiple firms, including Amgen Ventures and Kleiner Perkins.socaltech.comDomain Associates Raises $163.6M In New FundDomain Associates raised $163.6M in a new fund, Domain Partners IX, LP, according to a regulatory filing. The fund includes six limited partners and was managed by Jim Blair, Brian Dovey, Brian Halak, Nicole Vitullo, and Kim Kamdar. Fundraising began in December 2014.FinSMEsDomain Associates Closes Latest Life Sciences Venture Capital Fund, at $163.6MDomain Associates closed its latest life sciences venture capital fund at $163.6 million, subscribed by six investors. The firm, founded in 1985, has invested in over 260 life sciences companies and typically backs first institutional financing rounds.FinSMEsAxial Biotherapeutics Raises $19.15M in Series A FundingAxial Biotherapeutics raised $19.15 million in Series A funding led by Longwood Fund and Domain Associates. The Boston-based company develops gut-microbiome-based biotherapeutics for CNS disorders. It also appointed David H. Donabedian as CEO and board director.MedCity NewsAxial Biotherapeutics raises $19.15M to target gut-brain axisAxial Biotherapeutics launched on Wednesday with a $19.15M Series A led by Longwood Fund and Domain Associates. The company targets CNS disorders by modifying the gut microbiome, licensed from Caltech's Mazmanian Lab. It aims to build a microbiome discovery platform for underserved neurological diseases.